Company Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 17:39:54 06/05/2024 BST			5-day change	1st Jan Change
7.2 ^USD	+0.70%		+10.45%	+122.89%

03-27	Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating	MT
03-25	HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating	MT

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Number of employees: 140

Managers	Title	Age	Since
Talat Imran CEO	Chief Executive Officer	43	31/05/21
Mir Imran FOU	Founder	67	05/04/21
Svai Sanford DFI	Director of Finance/CFO	54	05/04/21
Jacques Van Dam CTO	Chief Tech/Sci/R&D Officer	-	31/12/20
Mir Hashim CTO	Chief Tech/Sci/R&D Officer	65	05/04/21
Bella Vazquez HRO	Human Resources Officer	-	30/06/21
Eric Groen LAW	General Counsel	53	08/09/21
Kate McKinley PRN	Corporate Officer/Principal	47	23/05/23
Arvinder Dhalla PRN	Corporate Officer/Principal	-	30/06/21
J. Christopher Prue LAW	General Counsel	-	30/06/21

Members of the board	Title	Age	Since
Laureen DeBuono BRD	Director/Board Member	66	05/04/21
Jean-Luc Butel BRD	Director/Board Member	67	05/04/21
Dennis Ausiello BRD	Director/Board Member	78	05/04/21
Mir Imran FOU	Founder	67	05/04/21
Andrew Farquharson BRD	Director/Board Member	55	05/04/21
Talat Imran CEO	Chief Executive Officer	43	31/05/21
Maulik Nanavaty BRD	Director/Board Member	62	05/04/21
Mir Hashim CTO	Chief Tech/Sci/R&D Officer	65	05/04/21
Lisa Rometty BRD	Director/Board Member	56	02/01/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	24,116,444	0	0	25.16 %
Stock B	1	29,298,553	13,441,300 ( 45.88 %)	3,000,000 ( 10.24 %)

Name	Equities	%	Valuation
South Cone Investments LP 46.59 %	12,131,554	46.59 %	38 M $
Vanguard Global Advisers LLC 2.567 %	668,347	2.567 %	2 M $
Pivotal Bioventure Partners Investment Advisor LLC 1.895 %	493,584	1.895 %	2 M $
Mir Imran 1.860 %	484,455	1.860 %	2 M $
United Services Automobile Association 1.848 %	481,300	1.848 %	1 M $
TEIJIN LIMITED 1.731 %	450,733	1.731 %	1 M $
ALPHABET INC. 1.722 %	448,492	1.722 %	1 M $
Talat Imran 0.6960 %	181,238	0.6960 %	563 650 $
Eric Groen 0.6268 %	163,216	0.6268 %	507 602 $
Mir Hashim 0.5699 %	148,415	0.5699 %	461 571 $

Name	Equities	%	Valuation
Mir Hashim -	374,119	-	1 M $
Andrew Farquharson -	242,421	-	753 929 $
Maulik Nanavaty -	155,118	-	482 417 $
Svai Sanford -	142,350	-	442 709 $
Dennis Ausiello -	92,074	-	286 350 $
Talat Imran -	43,484	-	135 235 $

Name	Equities	%	Valuation
In-Cube, Inc. 76.57 %	22,411,124	76.57 %	70 M $
Andrew Farquharson 0.7972 %	233,333	0.7972 %	725 666 $
Maulik Nanavaty 0.1807 %	52,878	0.1807 %	164 451 $
Mir Hashim 0.0876 %	25,649	0.0876 %	79 768 $

Rani Therapeutics Holdings, Inc.

2051 Ringwood Avenue

95131, San Jose

http://www.ranitherapeutics.com

address Rani Therapeutics Holdings, Inc.(RANI)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.15 USD

Average target price

8.857 USD

Spread / Average Target

+23.88%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
RANI THERAPEUTICS HOLDINGS, INC.	+122.89%	188M
REGENERON PHARMACEUTICALS, INC.	+8.49%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.18%	104B
ARGENX SE	+5.79%	22.94B
BIONTECH SE	-12.66%	22.34B
GENMAB A/S	-7.01%	19.25B
WUXI APPTEC CO., LTD.	-37.08%	17.08B
BEIGENE, LTD.	-9.43%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+8.05%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.95%	12.63B

Bio Therapeutic Drugs